In-depth scientific research drives long term conviction and support through company building, private financing and public markets.
The LifeSci team played an integral role in the formation and successful launch of Engage Therapeutics. At all times, I considered them part of my team. From the beginning, LifeSci guided me through the investor story, outreach process and strategy for closing.
We are honored by the magnitude of support from such an impressive syndicate of investors, especially during these turbulent times.
We are thrilled to have an incredibly strong, committed network of investors and plan to continue extending our leadership in the decentralized clinical trial market.
Dr. Kalfus was Chief Medical Officer at Thar Pharmaceuticals until its acquisition by Grunenthal in 2016. He was previously Vice President of Medical Affairs at Lev Pharmaceuticals, where he led the clinical development for Cinryze, the first HAE prophylaxis therapy, approved by the FDA in 2008. Upon the acquisition of Lev by ViroPharma Inc. in 2008, he consulted on the Cinryze commercial launch and expansion as well as investor relations activities for ViroPharma. Dr. Kalfus is consulting Medical Director at RedHill Biopharma Ltd. and directs two phase III clinical programs. His other positions have included Aetna/US Healthcare (Medical Director), Hillside Medical Associates (Internist), and Long Island Jewish Medical Center (President of the Staff Society and Chairman of Performance Improvement). Dr. Kalfus completed residency in Internal Medicine at Long Island Jewish Medical Center and graduated from Albert Einstein College of Medicine with an M.D. and Columbia University with a B.A. in Biology.
Visit Homepage